Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy

This publication has 42 references indexed in Scilit:

• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
  The Lancet, 2009
• Pemetrexed in first-line treatment of non-small cell lung cancer
  Cancer Treatment Reviews, 2009
• The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
  The Oncologist, 2009
• Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer
  Journal of Thoracic Oncology, 2008
• In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
  Investigational New Drugs, 2007
• Role of Pemetrexed in Non-Small Cell Lung Cancer
  Cancer Investigation, 2007
• Expression Profile–Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors
  Journal of Clinical Oncology, 2006
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
  Proceedings of the National Academy of Sciences, 2001
• Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors
  The Oncologist, 2001
• Reproducibility of neuroendocrine lung tumor classification
  Human Pathology, 1998